Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › FP7

SILVER · Small-molecule Inhibitor Leads Versus emerging and neglected RNA viruses

FP7Status: CLOSED1 October 201031 March 2015EU funding €12,000,000

RNA virus infections kill millions of humans annually, largely due to the lack of suitable vaccines and drugs to control them. This problem is addressed in this FP7 call and in response a consortium of Europe’s and Asia’s leading molecular virologists, structural biologists, medicinal chemists and bioinformaticians has been brought together to generate a state-of-the-art drug discovery and design programme. The project aims to identify Small molecule Inhibitor Leads Versus Emerging and neglected RNA viruses (SILVER). It will focus its activities on selected medically important RNA viruses for which the development of drugs is considered essential (Dengue-, entero- and paramyxoviruses), whereas other relatively neglected and/or emerging RNA viruses will be explored to identify the most promising viral protein targets and antiviral compounds. A pipeline strategy has been developed to enable the inclusion in SILVER of viruses at all levels of existing knowledge. Targets for potential drugs include infectious virus, structurally characterised viral enzymes and other proteins. Leads for currently available antiviral drugs have been identified by screening compound libraries in virus-infected cell culture systems and in vitro assays using purified viral enzymes. Selective inhibitors of viral replication have also been (and are being) derived using detailed structural knowledge of viral proteins and structure-based drug design. Hits will be assayed using individual viral protein targets and replicative proteins in complex with viral RNA. The potential protective activity of the most potent inhibitors, that have a favourable (in vitro) ADME-tox profile, will be assessed in relevant infection models in animals. Licenses on promising compounds or compound classes will be presented to the interested pharmaceutical industry. The SILVER consortium will be well placed to play a major role in contributing to the international effort to develop strategies to improve world health.

Consortium · 24 organisations

coordinator

UNIVERSITE D'AIX MARSEILLE

FR · €2,855,357

participant

STICHTING RADBOUD UNIVERSITEIT

NL · €144,983

participant

ACADEMISCH ZIEKENHUIS LEIDEN

NL · €744,610

participant

SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

CN · €175,000

participant

Global Phasing Limited

UK · €400,000

participant

UNIVERSITAET HAMBURG

DE · €375,000

participant

UNIVERSITAET LEIPZIG

DE · €282,675

participant

AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS

ES · €625,000

participant

National Central University

TW

participant

PIKE PHARMA GMBH

CH · €144,674

participant

INSTITUT PASTEUR

FR · €418,960

participant

UNIVERSITATSKLINIKUM HEIDELBERG

DE · €400,000

participant

UNIVERSITA DEGLI STUDI DI MILANO

IT · €543,000

participant

RIBOXX GMBH

DE · €361,720

participant

CENTRUM VOOR INNOVATIE EN STIMULATIE VAN MEDICIJNONTWIKKELING LEUVEN VZW

BE · €403,000

participant

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

UK · €500,000

participant

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM

NL · €589,400

participant

UNIVERSITEIT UTRECHT

NL · €230,017

participant

UNIVERSITAET INNSBRUCK

AT · €375,000

participant

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS

FR · €350,000

participant

KATHOLIEKE UNIVERSITEIT LEUVEN

BE · €993,880

participant

FREIE UNIVERSITAET BERLIN

DE · €142,325

participant

UNIVERSITAET zu LUEBECK

DE · €945,400

participant

KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

KR

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.